




# One place for your practice and patients— every step of the way

myAgios® Patient Support Services assists your patients with pyruvate kinase (PK) deficiency by providing personalized education and customized treatment support through a single point of engagement.



ACEs and PSMs do not provide medical advice. For medical advice or treatment-related questions, patients are instructed to talk to their healthcare team.

## INDICATION

PYRUKYND is a pyruvate kinase activator indicated for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency.



## IMPORTANT SAFETY INFORMATION

**Acute Hemolysis:** Acute hemolysis with subsequent anemia has been observed following abrupt interruption or discontinuation of PYRUKYND in a dose-ranging study. Avoid abruptly discontinuing PYRUKYND. Gradually taper the dose of PYRUKYND to discontinue treatment if possible. When discontinuing treatment, monitor patients for signs of acute hemolysis and anemia including jaundice, scleral icterus, dark urine, dizziness, confusion, fatigue, or shortness of breath.

**Please see additional Important Safety Information throughout and full Prescribing Information, including Patient Information.**

## Patient Education

## Prescription Support



# Your patients have a dedicated team at myAgios® Patient Support Services

**Agios Clinical Educators (ACEs) and Patient Support Managers (PSMs) are here to help guide your patients living with PK deficiency along every step of their journey.**



### What's an ACE?

An Agios Clinical Educator (ACE) is there from the start to offer personalized guidance to people living with PK deficiency with or without a prescription.

#### ACEs help your patients:

- Get introduced to the PSM to learn more about their health insurance options
- Learn about their disease
- Set goals for living with their condition and discuss treatment considerations
- Connect with other patients and hear from experts on webinars



### What's a PSM?

A Patient Support Manager (PSM) helps people prescribed PYRUKYND® (mitapivat) get access to and stay on PYRUKYND.

#### PSMs help your patients:

- Connect to ACEs to learn about their condition and PYRUKYND
- Understand financial assistance options and eligibility criteria
- Obtain resources and encouragement, starting at treatment initiation, through phone calls, emails, and SMS (text messages)

#### PSMs help you and your office:

- Navigate the patient's insurance coverage
- Address prior authorization requirements and appeals
- Coordinate all fulfillment and delivery with the exclusive specialty pharmacy

**The myAgios team communicates with patients in English and Spanish to help ensure understanding and comfort.**


ACEs and PSMs do not provide medical advice. For medical advice or treatment-related questions, patients are instructed to talk to their healthcare team.

### IMPORTANT SAFETY INFORMATION (cont.)

**Hepatocellular Injury in Another Condition:** In patients with another condition treated with PYRUKYND at a higher dose than that recommended for patients with PK deficiency, liver injury has been observed. These events were characterized by a time to onset within the first 6 months of treatment with peak elevations of alanine aminotransferase of  $>5\times$  upper limit of normal (ULN) with or without jaundice. All patients discontinued treatment with PYRUKYND, and these events improved upon treatment discontinuation.

Obtain liver tests prior to the initiation of PYRUKYND and monthly thereafter for the first 6 months and as clinically indicated. Interrupt PYRUKYND if clinically significant increases in liver tests are observed or alanine aminotransferase is  $>5\times$  ULN. Discontinue PYRUKYND if hepatic injury due to PYRUKYND is suspected.

**Please see additional Important Safety Information throughout and full Prescribing Information, including Patient Information.**



## All-in-one enrollment and support for your patients

**myAgios offers a single point of engagement for your office staff when seeking care for your patients living with PK deficiency.**

- 1 Personalized Patient Education**  
At diagnosis or when the patient wants to learn more, the **ACE** provides education and support
- 2 Prescription Support**  
To prescribe PYRUKYND®, you complete the PYRUKYND Start Form and your office submits it to myAgios 
- 3 Access and Assistance**  
**PSMs** work directly with your patients and your practice to discuss PYRUKYND and how to navigate insurance hurdles and coordinate delivery through the exclusive Specialty Pharmacy
- 4 Customized Treatment Support and Adherence**  
Patients can get help to prepare for appointments and get questions about PYRUKYND answered via text or call with their **ACEs** or **PSMs**



### myAgios can help patients determine their eligibility for programs to help them access PYRUKYND

<b>PYRUKYND Copay Program</b>	\$0 responsibility for commercially insured patients, regardless of how much they make
<b>Patient Assistance Program</b>	Free prescriptions for eligible patients who are uninsured or who do not have coverage for PYRUKYND
<b>Coverage Interruption Program</b>	Free prescriptions for eligible patients experiencing an interruption in their insurance coverage. Patients with government health insurance plans are not eligible.

Full terms and conditions are available at PYRUKYND.myAgios.com.

**Find information on financial assistance by visiting PYRUKYND.myAgios.com.**

### IMPORTANT SAFETY INFORMATION (cont.)

**Adverse Reactions:** The most common adverse reactions including laboratory abnormalities ( $\geq 10\%$ ) in patients with PK deficiency were estrone decreased (males), increased urate, back pain, estradiol decreased (males), and arthralgia.

**Please see additional Important Safety Information throughout and full Prescribing Information, including Patient Information.**



**pyrukyn**  
(mitapivat) tablets  
5 · 20 · 50 mg

**my**agios

The myAgios® Patient Support Services team provides personalized patient education, access, and assistance to your practice and customized treatment support for patients along each unique disease journey with PK deficiency

## Tools to support your patients and your practice

- » **myAgios patient brochure:**  
For patients to learn about myAgios Patient Support Services
- » **PYRUKYND® patient brochure:**  
For patients to understand treatment and monitoring needs
- » **Monitoring guides:**  
To help your patients, and your practice, monitor their symptoms
- » **Insurance 101 guide:**  
For patients to learn the basics of insurance and speak with their PSM
- » **PYRUKYND website:**  
For clinical data on PYRUKYND, and helpful resources
- » **PYRUKYND Start Form:**  
Submit the prescription electronically



Scan to prescribe PYRUKYND and connect your patient to myAgios.  
Visit [pyrkynd.myagios.com/hcp](http://pyrkynd.myagios.com/hcp) for the PYRUKYND Start Form and more.

## IMPORTANT SAFETY INFORMATION (cont.)

### Drug Interactions:

- Strong CYP3A Inhibitors and Inducers: Avoid concomitant use.
- Moderate CYP3A Inhibitors: Do not titrate PYRUKYND beyond 20 mg twice daily.
- Moderate CYP3A Inducers: Consider alternatives that are not moderate inducers. If there are no alternatives, adjust PYRUKYND dosage.
- Sensitive CYP3A, CYP2B6, CYP2C Substrates Including Hormonal Contraceptives: Avoid concomitant use with substrates that have narrow therapeutic index.
- UGT1A1 Substrates: Avoid concomitant use with substrates that have narrow therapeutic index.

- P-gp Substrates: Avoid concomitant use with substrates that have narrow therapeutic index.

**Hepatic Impairment:** Avoid use of PYRUKYND in patients with moderate and severe hepatic impairment.

**Please see additional Important Safety Information throughout and full Prescribing Information, including Patient Information.**